PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer ; volume:10 ; number:2 ; day:27 ; month:3 ; year:2008 ; pages:1-10 ; date:4.2008
Breast cancer research ; 10, Heft 2 (27.3.2008), 1-10, 4.2008
- Urheber
-
Liedtke, Cornelia
- Beteiligte Personen und Organisationen
-
Cardone, Luca
Tordai, Attila
Yan, Kai
Gomez, Henry L.
Figureoa, Luis J Barajas
Hubbard, Rebekah E.
Valero, Vicente
Souchon, Eduardo A.
Symmans, W Fraser
Hortobagyi, Gabriel N.
Bardelli, Alberto
Pusztai, Lajos
SpringerLink (Online service)
- DOI
-
10.1186/bcr1984
- URN
-
urn:nbn:de:1111-201603241076
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liedtke, Cornelia
- Cardone, Luca
- Tordai, Attila
- Yan, Kai
- Gomez, Henry L.
- Figureoa, Luis J Barajas
- Hubbard, Rebekah E.
- Valero, Vicente
- Souchon, Eduardo A.
- Symmans, W Fraser
- Hortobagyi, Gabriel N.
- Bardelli, Alberto
- Pusztai, Lajos
- SpringerLink (Online service)
Ähnliche Objekte (12)
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
PIK3CA-mutations in breast cancer
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
PIK3CA mutations in endocrine-resistant breast cancer
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations
Activating FGFR1 Mutations in Sporadic Pheochromocytomas
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
PIK3CA-mutations in breast cancer
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
PIK3CA mutations in endocrine-resistant breast cancer
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations
Activating FGFR1 Mutations in Sporadic Pheochromocytomas
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
PIK3CA-mutations in breast cancer
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
PIK3CA mutations in endocrine-resistant breast cancer
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations